View Item 

Show simple item record

Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient‐Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II
dc.contributor.authorVolkmann, Elizabeth R.
dc.contributor.authorTashkin, Donald P.
dc.contributor.authorLeClair, Holly
dc.contributor.authorRoth, Michael D.
dc.contributor.authorKim, Grace
dc.contributor.authorGoldin, Jonathan
dc.contributor.authorClements, Philip J.
dc.contributor.authorFurst, Daniel E.
dc.contributor.authorKhanna, Dinesh
dc.date.accessioned2020-07-02T20:34:48Z
dc.date.availableWITHHELD_12_MONTHS
dc.date.available2020-07-02T20:34:48Z
dc.date.issued2020-06
dc.identifier.citationVolkmann, Elizabeth R.; Tashkin, Donald P.; LeClair, Holly; Roth, Michael D.; Kim, Grace; Goldin, Jonathan; Clements, Philip J.; Furst, Daniel E.; Khanna, Dinesh (2020). "Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient‐Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II." ACR Open Rheumatology 2(6): 362-370.
dc.identifier.issn2578-5745
dc.identifier.issn2578-5745
dc.identifier.urihttps://hdl.handle.net/2027.42/156000
dc.publisherWiley Periodicals, Inc.
dc.publisherQualityMetric Incorporated
dc.titleTreatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient‐Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelRheumatology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/156000/1/acr211125.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/156000/2/acr211125_am.pdf
dc.identifier.doi10.1002/acr2.11125
dc.identifier.sourceACR Open Rheumatology
dc.identifier.citedreferenceBirring S, Muccino D, Bacci ED, Vernon MK, Nguyen AM. Defining minimal clinically important differences (MCID) on the Leicester Cough Questionnaire (LCQ): analyses of a phase 2 randomized controlled trial in chronic cough. J Allergy Clin Immunol 2019; 143 Suppl: AB52.
dc.identifier.citedreferenceBeretta L, Santaniello A, Lemos A, Masciocchi M, Scorza R. Validity of the Saint George’s Respiratory Questionnaire in the evaluation of the health‐related quality of life in patients with interstitial lung disease secondary to systemic sclerosis. Rheumatology (Oxford) 2007; 46: 296 – 301.
dc.identifier.citedreferenceKhanna D, Hays RD, Maranian P, Seibold JR, Impens A, Mayes MD, et al. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum 2009; 61: 1257 – 63.
dc.identifier.citedreferenceClements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M, White B, et al. Correlates of the disability index of the Health Assessment Questionnaire: a measure of functional impairment in systemic sclerosis. Arthritis Rheum 1999; 42: 2372 – 80.
dc.identifier.citedreferenceKhanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, et al. Responsiveness of the SF‐36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol 2005; 32: 832 – 40.
dc.identifier.citedreferenceBarr JT, Schumacher GE, Freeman S, LeMoine M, Bakst AW, Jones PW. American translation, modification, and validation of the St. George’s Respiratory Questionnaire. Clin Ther 2000; 22: 1121 – 45.
dc.identifier.citedreferenceWallace B, Kafaja S, Furst DE, Berrocal VJ, Merkel PA, Seibold JR, et al. Reliability, validity and responsiveness to change of the Saint George’s Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis. Rheumatology (Oxford) 2015; 54: 1369 – 79.
dc.identifier.citedreferenceBae S, Allanore Y, Furst DE, Bodukam V, Coustet B, Morgaceva O, et al. Associations between a scleroderma‐specific gastrointestinal instrument and objective tests of upper gastrointestinal involvements in systemic sclerosis. Clin Exp Rheumatol 2013; 31 Suppl 76: 57 – 63.
dc.identifier.citedreferenceMcMahan ZH, Frech T, Berrocal V, Lim D, Bruni C, Matucci‐Cerinic M, et al. Longitudinal assessment of patient‐reported outcome measures in systemic sclerosis patients with gastroesophageal reflux disease: Scleroderma Clinical Trials Consortium. J Rheumatol 2019; 46: 78 – 84.
dc.identifier.citedreferenceJaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407 – 15.
dc.identifier.citedreferenceAngst F, Aeschlimann A, Stucki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF‐36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis Rheum 2001; 45: 384 – 91.
dc.identifier.citedreferenceKhanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR, et al. Minimally important difference in diffuse systemic sclerosis: results from the D‐penicillamine study. Ann Rheum Dis 2006; 65: 1325 – 9.
dc.identifier.citedreferenceKhanna D, Furst DE, Maranian P, Seibold JR, Impens A, Mayes MD, et al. Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. J Rheumatol 2011; 38: 1920 – 4.
dc.identifier.citedreferenceWitek TJ Jr, Mahler DA. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 2003; 56: 248 – 55.
dc.identifier.citedreferenceJones PW. St. George’s Respiratory Questionnaire: MCID. COPD 2005; 2: 75 – 9.
dc.identifier.citedreferenceCohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale (NJ): Lawrence Erlbaum Associates; 1988.
dc.identifier.citedreferenceLi N, Elashoff RM, Li G, Tseng CH. Joint analysis of bivariate longitudinal ordinal outcomes and competing risks survival times with nonparametric distributions for random effects. Stat Med 2012; 31: 1707 – 21.
dc.identifier.citedreferenceGoldin JG, Kim GH, Tseng CH, Volkmann E, Furst D, Clements P, et al. Longitudinal changes in quantitative interstitial lung disease on computed tomography after immunosuppression in the Scleroderma Lung Study II. Ann Am Thorac Soc 2018; 15: 1286 – 95.
dc.identifier.citedreferenceFernandez‐Codina A, Walker KM, Pope JE, Scleroderma Algorithm Group. Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol 2018; 70: 1820 – 8.
dc.identifier.citedreferenceNamas R, Tashkin DP, Furst DE, Wilhalme H, Tseng CH, Roth MD, et al. Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo‐controlled trials. Arthritis Care Res (Hoboken) 2018; 70: 439 – 44.
dc.identifier.citedreferenceKafaja S, Clements PJ, Wilhalme H, Tseng CH, Furst DE, Kim GH, et al. Reliability and minimal clinically important differences of forced vital capacity: results from the Scleroderma Lung Studies (SLS‐I and SLS‐II). Am J Resp Crit Care Med 2018; 197: 644 – 52.
dc.identifier.citedreferenceVolkmann ER, Tashkin DP, Sim M, Li N, Khanna D, Roth MD, et al. Cyclophosphamide for systemic sclerosis‐related interstitial lung disease: a comparison of Scleroderma Lung Study I and II. J Rheumatol 2019; 46: 1316 – 25.
dc.identifier.citedreferenceTashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, et al. Effects of 1‐year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176: 1026 – 34.
dc.identifier.citedreferenceKhanna D, Hays RD, Furst DE. Functional disability and other health‐related quality‐of‐life domains: points to consider for clinical trials in systemic sclerosis. Rheumatology (Oxford) 2017; 56 Suppl 5: v17 – 22.
dc.identifier.citedreferenceLumetti F, Baron L, Alfieri C, Silva M, Serra V, Delsante G, et al. Quality of life and functional disability in patients with interstitial lung disease related to systemic sclerosis. Acta Biomed 2015; 86: 142 – 8.
dc.identifier.citedreferenceHudson M, Thombs BD, Steele R, Panopalis P, Newton E, Baron M, et al. Health‐related quality of life in systemic sclerosis: a systematic review. Arthritis Rheum 2009; 61: 1112 – 20.
dc.identifier.citedreferenceKhanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, et al. Impact of oral cyclophosphamide on health‐related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum 2007; 56: 1676 – 84.
dc.identifier.citedreferenceDistler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis‐associated interstitial lung disease. N Engl J Med 2019; 380: 2518 – 28.
dc.identifier.citedreferenceTashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655 – 66.
dc.identifier.citedreferenceTashkin DP, Volkmann ER, Tseng CH, Roth MD, Khanna D, Furst DE, et al. Improved cough and cough‐specific quality of life in patients treated for scleroderma‐related interstitial lung disease: results of Scleroderma Lung Study II. Chest 2017; 151: 813 – 20.
dc.identifier.citedreferenceTheodore AC, Tseng CH, Li N, Elashoff RM, Tashkin DP. Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study. Chest 2012; 142: 614 – 21.
dc.identifier.citedreferenceTashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma‐related interstitial lung disease (SLS II): a randomized controlled, double‐blind, parallel group trial. Lancet Resp Med 2016; 4: 708 – 19.
dc.identifier.citedreferenceSubcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581 ‐ 90.
dc.identifier.citedreferenceMahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751 – 8.
dc.identifier.citedreferenceKim HJ, Tashkin DP, Clements PJ, Li G, Brown MS, Elashoff R, et al. A computer‐aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients. Clin Exp Rheumatol 2010; 28 Suppl 62: S26 – 35.
dc.identifier.citedreferenceSaris‐Baglama RN, Dewey CJ, Chisholm GB, Plumb E, King J, Kosinski MA, et al. QualityMetric health outcomes™ scoring software 4.0: installation guide. Lincoln (RI): QualityMetric Incorporated; 2010.
dc.identifier.citedreferenceFries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137 – 45.
dc.identifier.citedreferenceMahler DA, Ward J, Fierro‐Carrion G, Waterman LA, Lentine TF, Mejia‐Alfaro R, et al. Development of self‐administered versions of modified baseline and transition dyspnea indexes in COPD. COPD 2004; 1: 165 – 72.
dc.identifier.citedreferenceBirring SS, Prudon B, Carr AJ, Singh SJ, Morgan MD, Pavord ID. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax 2003; 58: 339 – 43.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
acr211125.pdf
Size:
338.1KB
Format:
PDF
View/Open
Name:
acr211125_am.pdf
Size:
280.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.